Zeimet AG - Search Results

1

An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.

Wieser V, Tsibulak I, Reimer DU, Zeimet AG, Fiegl H, Hackl H, Marth C. Wieser V, et al. Among authors: zeimet ag. Gynecol Oncol. 2023 Mar;170:290-299. doi: 10.1016/j.ygyno.2023.01.034. Epub 2023 Feb 7. Gynecol Oncol. 2023. PMID: 36758419 Free article.

2

High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.

Wolf AM, Rumpold H, Reimer D, Marth C, Zeimet AG, Wolf D. Wolf AM, et al. Among authors: zeimet ag. Gynecol Oncol. 2010 Sep;118(3):244-50. doi: 10.1016/j.ygyno.2010.05.024. Epub 2010 Jun 17. Gynecol Oncol. 2010. PMID: 20603238

3

DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.

Zeimet AG, Fiegl H, Goebel G, Kopp F, Allasia C, Reimer D, Steppan I, Mueller-Holzner E, Ehrlich M, Marth C. Zeimet AG, et al. Gynecol Oncol. 2011 Apr;121(1):24-31. doi: 10.1016/j.ygyno.2010.12.332. Epub 2011 Jan 20. Gynecol Oncol. 2011. PMID: 21251700 Free PMC article.

4

TNFα signalling predicts poor prognosis of patients with endometrial cancer.

Wieser V, Abdel Azim S, Sprung S, Knoll K, Kögl J, Hackl H, Marth C, Zeimet AG, Fiegl H. Wieser V, et al. Among authors: zeimet ag. Carcinogenesis. 2020 Aug 12;41(8):1065-1073. doi: 10.1093/carcin/bgaa034. Carcinogenesis. 2020. PMID: 32301486

5

Dubious effects of methadone as an "anticancer" drug on ovarian cancer cell-lines and patient-derived tumor-spheroids.

Fiegl H, Hagenbuchner J, Kyvelidou C, Seeber B, Sopper S, Tsibulak I, Wieser V, Reiser E, Roessler J, Huhtinen K, Carpén O, Parson W, Sprung S, Marth C, Ausserlechner MJ, Zeimet AG. Fiegl H, et al. Among authors: zeimet ag. Gynecol Oncol. 2022 Apr;165(1):129-136. doi: 10.1016/j.ygyno.2022.01.008. Epub 2022 Jan 13. Gynecol Oncol. 2022. PMID: 35033381 Free article.

6

Prognostic value of CD44 splice variant expression in ovarian cancer.

Uhl-Steidl M, Müller-Holzner E, Zeimet AG, Adolf GR, Daxenbichler G, Marth C, Dapunt O. Uhl-Steidl M, et al. Among authors: zeimet ag. Oncology. 1995 Sep-Oct;52(5):400-6. doi: 10.1159/000227497. Oncology. 1995. PMID: 7543667

7

Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125.

Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O. Zeimet AG, et al. Gynecol Oncol. 1996 Sep;62(3):384-9. doi: 10.1006/gyno.1996.0253. Gynecol Oncol. 1996. PMID: 8812537

8

Biological markers in pT1 and pT2 ovarian cancer with lymph node metastases.

Concin N, Hefler L, van Bavel J, Mueller-Holzner E, Zeimet A, Daxenbichler G, Speiser P, Hacker N, Marth C. Concin N, et al. Gynecol Oncol. 2003 Apr;89(1):9-15. doi: 10.1016/s0090-8258(02)00147-6. Gynecol Oncol. 2003. PMID: 12694648

9

Why did p53 gene therapy fail in ovarian cancer?

Zeimet AG, Marth C. Zeimet AG, et al. Lancet Oncol. 2003 Jul;4(7):415-22. doi: 10.1016/s1470-2045(03)01139-2. Lancet Oncol. 2003. PMID: 12850192 Review.

10

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

Spizzo G, Went P, Dirnhofer S, Obrist P, Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G, Zeimet AG. Spizzo G, et al. Among authors: zeimet ag. Gynecol Oncol. 2006 Nov;103(2):483-8. doi: 10.1016/j.ygyno.2006.03.035. Epub 2006 May 6. Gynecol Oncol. 2006. PMID: 16678891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

199 results

Search Page